<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The aim of this study was to evaluate the effect of rifampin (the "rifampin test") on serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> in patients with and without <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: We conducted a clinical trial in which the effect of rifampin on serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> level in 15 patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> was compared with 10 patients without <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> (controls) in a General Internal Medicine/Primary Care clinic of a Veterans Affairs medical center </plain></SENT>
<SENT sid="2" pm="."><plain>Each participant underwent a "rifampin test," i.e., <z:chebi fb="0" ids="16990">bilirubin</z:chebi> measurement at baseline and 2, 4, and 6 h after the administration of 900 mg of rifampin </plain></SENT>
<SENT sid="3" pm="."><plain>Measurements included complete blood count, blood chemistry including liver panel tests (ALP, AST, LDH, and albumin) along with total serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels </plain></SENT>
<SENT sid="4" pm="."><plain>Ten patients with Gilbert's and nine control patients had haptoglobin level measured at baseline and 6 h after the administration of rifampin </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: While fasting, the mean rise in total serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> at 2, 4, and 6 h after the administration of rifampin, respectively, was 0.5, 0.7, and 0.7 mg/dl (analysis of variance, p &lt; 0.001) in control patients and 0.6, 1.0, and 1.1 mg/dl (p &lt; 0.001) in the study patients </plain></SENT>
<SENT sid="6" pm="."><plain>In 15 fed subjects (six control and nine study), the mean rise in total serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> at 2, 4, and 6 h, respectively, was 0.3, 0.5, and 0.6 mg/dl (p &lt; 0.001) in controls and 0.5, 1.0, and 1.2 mg/dl (p &lt; 0.001) in study subjects </plain></SENT>
<SENT sid="7" pm="."><plain>In the fasting state, rise in total serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> to &gt;1.9 mg/dl distinguished patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> from those without at 2, 4, and 6 h (sensitivity 100%, 93%, and 93%; specificity 100%, 100%, and 100% at 2, 4, and 6 h, respectively) </plain></SENT>
<SENT sid="8" pm="."><plain>In the nonfasting state, rise in total serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> to &gt; 1.5 mg/dl at 4 and 6 h after rifampin administration distinguished the two groups (sensitivity 90% and 100%; specificity 100% and 100%, respectively) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Rifampin increases total serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels in patients with and without <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>On fasting for 12 to 24 h, an absolute increase of <z:chebi fb="0" ids="16990">bilirubin</z:chebi> to &gt;1.9 mg/dl 2 to 6 h after the administration of 900 mg of rifampin distinguishes patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> from those without it </plain></SENT>
<SENT sid="11" pm="."><plain>In the nonfasting state, an increase in total serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> to &gt; 1.5 mg/dl 4 to 6 h after the administration of rifampin distinguishes persons with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> from those without it </plain></SENT>
</text></document>